Now's the time to find biomarkers on purpose

Annals of Oncology

Volumn 21, Issue 2, 2010, Pages 193-194

  Auman, J T ^a   McLeod, H L ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; TUMOR MARKER; ANTINEOPLASTIC AGENT; PHARMACOLOGICAL BIOMARKER;

CANCER PROGNOSIS; CANCER RESEARCH; CANCER SURVIVAL; DRUG RESPONSE; EDITORIAL; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; GENE DOSAGE; GENE EXPRESSION PROFILING; HUMAN; LUNG NON SMALL CELL CANCER; PATIENT SELECTION; PRIORITY JOURNAL; RECEPTOR GENE; DRUG DEVELOPMENT; GENETIC ASSOCIATION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; NEOPLASM; NOTE; ONCOGENE RAS; PROTO ONCOGENE; RESEARCH;

ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; DRUG DISCOVERY; GENE EXPRESSION PROFILING; GENES, ERBB-1; GENES, ERBB-2; GENES, RAS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; NEOPLASMS; RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 77951915863     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp571     Document Type: Editorial

References (9)

1. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
2. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007; 18: 977-984.
3. Zhu C-Q, da Cunha Santos G, Ding K et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26: 4268-4275.
4. Normanno N, Tejpar S, Morgillo F et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009; 6: 519-527.
5. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
6. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of nonsmall- cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792.
7. Auman JT, McLeod HL. Cancer pharmacogenomics: DNA genotyping and gene expression profiling to identify molecular determinants of chemosensitivity. Drug Metab Rev 2008; 40: 303-315.
8. Tan EH, Ramlau R, Pluzanska A et al. A multi-centre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. Ann Oncol 2010; 21: 217-222.
9. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.